Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the potential of CAR-T cell therapy in treating relapsed/refractory autoimmune disorders. This strategy is a promising step toward creating a potentially curable treatment for CIDP.
CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory autoimmune disorders
Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the potential of CAR-T cell therapy in treating relapsed/refractory autoimmune disorders. This strategy is a promising step toward creating a potentially curable treatment for CIDP.